NM is a biotech company commercialising nano-enabled delivery platforms which have the ability to delivery low molecular weight drugs, small peptides, and nucleic acids across various biological barriers. In particular, its MET technology has been shown to be able to overcome and bypass the BBB. NM has nano-enabled lead products due to commence clinical development. It has a specialist management team including founding scientists who are leading experts in the application of pharmaceutical nanotechnology (Prof AG Schatzlein, Prof IF Uchegbu) and experienced experts (e.g. A. Bye ex VP Discovery Medicine GSK) with extensive drug development experience, in particular with respect to the CNS. Nanomerics will provide input into WP3 Task 4 with a particular view to planning of the potential clinical and commercial development of therapeutic solutions emerging from the consortium.

Social Media